Equillium Expands its Exclusive Licensing Agreement with Biocon for Itolizumab

 Equillium Expands its Exclusive Licensing Agreement with Biocon for Itolizumab

Equillium Expands its Exclusive Licensing Agreement with Biocon for Itolizumab

Shots:

  • Under the expanded collaboration, Equillium gets an exclusive right to develop and commercialize Biocon’s itolizumab in Australia and New Zealand. In May’2017, Biocon partnered with Equillium to develop a therapy for autoimmune disorders under which Equillium has granted an exclusive right for the therapy in the US and Canada
  • The expansion will allow Equillium to strengthen its footprints in Australia and New Zealand where it is collaborating with asthma centers and specialists to conduct the EQUIP clinical study in patients with uncontrolled asthma
  • Biocon’s Itolizumab (ALZUMAb in India) is a novel first-in-class humanized anti-CD6 mAb, indicated to treat moderate to severe PsO and has received the FDA’s FT designation for aGVHD and LN and ODD for treatment & prevention of aGVHD. Equillium is evaluating itolizumab in P-Ib PoC clinical study for aGVHD and LN

Click here to­ read full press release/ article | Ref: Biocon | Image: GlobeNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post